TCS among ICICI Securities top 5 bets with upside potential of up to 26% in 1 year

ICICI Securities has outlined a long-term statistical roadmap for the Nifty, identifying a risk-reward range of 24,200 to 29,200 for CY-26. According to the brokerage, every major correction since COVID-19 has found stability around the 24,200 zone, making it a reliable support base.

On the upside, historical price action shows that strong market phases have touched the upper statistical band. Based on this trend, ICICI Securities projects 29,500 as a realistic upside level if bullish momentum sustains through 2026. Given this backdrop, ICICI Securities has also recommended its top 5 bets for a horizon of 12 months and with an upside potential of up to 26%:

ICICI Securities has set a bullish target of Rs 180 for Bank of India. The suggested buying range is between Rs 132 and Rs 140, while the stop loss is placed at Rs 115. This forecast reflects a promising upside potential of 25.9% over the next 12 months.

For Marico Ltd, the brokerage expects the stock to scale up to Rs 880. Investors are advised to accumulate between Rs 710 and Rs 740, with a stop loss of Rs 638. The projected upside here is 19%, driven by steady FMCG performance and margin improvement.

ICICI Securities recommends accumulating TCS between Rs 3,120 and Rs 3,220, placing a stop loss at Rs 2,840. With a 12-month target pegged at Rs 3,775, this IT major offers a potential return of 14.8%, amid expectations of a pickup in tech spending.

The final pick on the list is Sun Pharma, with a target of Rs 2,180. The buying range advised is Rs 1,750 to Rs 1,790, with a stop loss at Rs 1,540. This setup indicates a 25% upside potential, backed by strong domestic and export pharma momentum.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)